The startup company Gilbert R&D B.V., a subsidiary of Gilbert B.V., announces today that it has received funding for the development of a new generation soft mist inhalers for the precise administration of expensive medicines for people with lung disease. Gilbert has received financing from Brabant Startup Fonds B.V. (“BSF”).
English: Click here for the full text press release.
Dutch: Click here for the full text press release.
Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for lung patients. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.
Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.
Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.